Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCLG-AML2019 supplementary venetoclax study in pediatric AML
ChiCTR2200058925Phase 4Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of venetoclax in acute myeloid leukemia (AML) (4 arms), sponsored by Beijing Children's Hospital. Primary endpoints: Bone marrow remission status, Minimal residual disease and 1 more. Started Apr 2022; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2200058925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058925.